Abstract:<p>To test the hypothesis that transient nonischemic stimulation of hypertrophy would render the heart resistant to subsequent ischemic stress, short-term transverse aortic constriction (TAC) was performed in mice and then withdrawn for several days by aortic debanding, followed by subsequent myocardial exposure to ischemia/reperfusion (I/R). Following I/R injury, the myocardial infarct size and apoptosis were markedly reduced, and contractile function was significantly improved in the TAC preconditioning group compared with the control group. Mechanistically, hypertrophic preconditioning remarkably alleviated I/R-induced oxidative stress, as evidenced by the increased NADPH/NADP ratio, increase in the GSH/GSSH ratio, and reduced mitochondrial ROS production. Moreover, TAC preconditioning inhibited caspase-3 activation and mitigated the mitochondrial impairment by deacetylating isocitrate dehydrogenase 2 (IDH2) via a SIRT3-dependent mechanism. In addition, the expression of a genetic deacetylation mimetic IDH2 mutant (IDH2 K413R) in cardiomyocytes, which increased IDH2 enzymatic activity and decreased mitochondrial ROS production, and ameliorated I/R injury, whereas the expression of a genetic acetylation mimetic (IDH2 K413Q) in cardiomyocytes abolished these protective effects of hypertrophic preconditioning. Furthermore, both the activity and expression of the SIRT3 protein were markedly increased in preconditioned mice exposed to I/R. Treatment with an adenovirus encoding SIRT3 partially emulated the actions of hypertrophic preconditioning, whereas genetic ablation of SIRT3 in mice blocked the cardioprotective effects of hypertrophic preconditioning. The present study identifies hypertrophic preconditioning as a novel endogenous self-defensive and cardioprotective strategy for cardiac I/R injury that induces IDH2 deacetylation through a SIRT3-dependent mechanism. A therapeutic strategy targeting IDH2 may be a promising treatment for cardiac ischemic injury.</p>

What problem does this paper attempt to address?

This paper aims to explore whether brief non - ischemic myocardial hypertrophic preconditioning can reduce cardiac ischemia/reperfusion (I/R) injury through the deacetylation of isocitrate dehydrogenase 2 (IDH2). Specifically, the researchers hypothesized that myocardial hypertrophy induced by short - term transverse aortic constriction (TAC), followed by the release of pressure load, could enhance the heart's resistance to subsequent ischemia/reperfusion injury, and this protective effect was achieved through the SIRT3 - dependent IDH2 deacetylation mechanism. The main findings of the study include: 1. **Myocardial hypertrophic preconditioning reduces I/R - induced cell death and cardiac dysfunction**: Mild myocardial hypertrophy was induced by 3 - or 7 - day TAC, then the constriction was released, and I/R treatment was performed. The results showed that compared with the control group, the myocardial infarction area in mice pretreated with TAC after I/R was significantly reduced, the myocardial cell apoptosis response was weakened, and cardiac functions (such as left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS)) were improved. 2. **Myocardial hypertrophic preconditioning alleviates oxidative - stress - mediated apoptotic signals**: Pretreatment significantly increased the uptake of 18F - FDG in the myocardium, indicating an increase in viable myocardium; at the same time, pretreatment also significantly reduced I/R - induced oxidative stress, as manifested by an increased NADPH/NADP ratio, an increased GSH/GSSG ratio, and a reduction in mitochondrial superoxide anion production. 3. **Myocardial hypertrophic preconditioning activates the SIRT3 signaling pathway**: The study found that myocardial hypertrophic preconditioning significantly increased the activity and expression of SIRT3, and the activation of SIRT3 further promoted the deacetylation of IDH2, enhanced the enzymatic activity of IDH2, thereby reducing the production of mitochondrial ROS and protecting the heart from I/R injury. These results suggest that myocardial hypertrophic preconditioning may be a new endogenous self - defense and cardioprotective strategy, reducing cardiac I/R injury through the SIRT3 - dependent IDH2 deacetylation mechanism. This finding provides a theoretical basis for the development of treatment strategies targeting IDH2 and is expected to become a new method for treating cardiac ischemic injury.

Hypertrophic preconditioning attenuates myocardial ischemia/reperfusion injury through the deacetylation of isocitrate dehydrogenase 2